GlassScriptPhysician profile
Eduardo Cabrera
NPI 1831337930
$1,494.42
in general payments reported to CMS, 2019-2025
24 companies · $214 in 2025
The $214 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $227 · 2020: $128 · 2022: $334 · 2023: $349 · 2024: $243 · 2025: $214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $806.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $805.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $329.53 | 2019-2025 | Rybelsus, Ozempic, Tresiba |
| Pfizer INC. | $163.12 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $127.35 | 2022-2024 | |
| Abbott Laboratories | $124.84 | 2022-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $115.55 | 2019-2025 | Trelegy Ellipta |
| Amarin Pharma, INC. | $85.78 | 2019-2022 | |
| Abbvie INC. | $51.79 | 2023-2024 | Vraylar |
| Lilly USA, LLC | $50.92 | 2019-2025 | Jardiance |
| Amgen INC. | $44.94 | 2019-2025 | Otezla, Repatha |
| Exact Sciences Corporation | $42.12 | 2024-2025 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $41.08 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $39.57 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $28.40 | 2023 | Rexulti |
| Boston Scientific Corporation | $27.40 | 2022 | |
| Insulet Corporation | $26.90 | 2025 | Omnipod |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $26.08 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.63 | 2020 | |
| Edwards Lifesciences Corporation | $23.62 | 2025 | |
| Allergan, INC. | $23.34 | 2019 | |
| Horizon Therapeutics Plc | $21.63 | 2023 | Krystexxa |
| Genzyme Corporation | $21.50 | 2024 | |
| Inogen, INC. | $21.13 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Genentech USA, INC. | $16.50 | 2019 | |
| Shire North American Group INC | $15.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eduardo Cabrera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.